Aprepitant

Evidence Level: L5

Predicted Indications: 10

Aprepitant

Pharmacist Assessment Report

Aprepitant: From an Approved Antiemetic Product to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Aprepitant is marketed in Canada under the EMEND brand. The approved indication text was not available in the data compiled for this report. The TxGNN model predicts it may be effective for nephrogenic syndrome of inappropriate antidiuresis. No clinical trials and no relevant publications currently support this prediction, so it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report
Predicted New Indication	Nephrogenic syndrome of inappropriate antidiuresis
TxGNN Prediction Score	0.9997
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Aprepitant is known to be a substance P/NK1 receptor antagonist. Its approved indication text could not be retrieved, so its established use cannot be compared directly with the predicted indication.

Nephrogenic syndrome of inappropriate antidiuresis is caused by gain-of-function of the vasopressin V2 receptor. No established link exists between NK1 blockade and this pathway. NK1 signaling may modulate central fluid and osmoregulation, but this is speculative.

The high TxGNN score is therefore not backed by mechanistic or clinical support at this time. The prediction should be treated as a computational hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02298813	EMEND TRI-PACK	Not listed	Not listed
02298805	EMEND	Not listed	Not listed
02298791	EMEND	Not listed	Not listed

Safety Considerations

Knowledge-graph contraindication signal: The TxGNN knowledge graph links aprepitant to a contraindication with liver failure. This comes from graph data, not from product label text.
Drug Interactions: 100 interactions were identified, and the first 20 returned are summarized here.
- Major: fentanyl, alfentanil, acalabrutinib
- Moderate (examples): paclitaxel, abemaciclib, rabeprazole, nifedipine, ibuprofen, levonorgestrel, hydrocortisone, albendazole, fluvoxamine, fosamprenavir, fosphenytoin, fostamatinib, gefitinib, lidocaine, dihydrocodeine, abametapir (topical)
- Minor: dolutegravir
Interaction levels come from the DDInter database. Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a high model score but no supporting clinical trials or relevant literature, and no plausible mechanistic link to the vasopressin V2 receptor pathway. The evidence level is L5. Package insert safety data and approved indication text are also missing.

To proceed, the following is needed:

Package insert warnings, contraindications and approved indications from Health Canada
Mechanism of action data from DrugBank, and an analysis of any link between NK1 signaling and renal water handling
Preclinical or mechanistic studies testing NK1 antagonism in models of nephrogenic syndrome of inappropriate antidiuresis
A review of the liver failure contraindication signal and the major drug interactions before any further evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.